Videos

Addition of Durvalumab, Bevacizumab to TACE for Hepatocellular Carcinoma Improves PFS

Featuring Riccardo Lencioni, MD

01/23/2024

At the ASCO Gastrointesinal Cancers Symposium, Riccardo Lencioni, MD, Pisa University School of Medicine, Pisa, Italy, discussed the results from the phase 3 EMERALD-1 study. This trial found the combination of transarterial chemoembolization (TACE) and durvalumab, followed by durvalumab and bevacizumab, improved the progression-free survival (PFS) among patients with hepatocellular carcinoma, compared with TACE alone.

Source:

Lencioni R, Kudo M, Erinjeri J, et al. EMERALD-1: A phase 3, randomized, placebo-controlled study of transarterial chemoembolization combined with durvalumab with or without bevacizumab in participants with unresectable hepatocellular carcinoma eligible for embolization. Presented at 2024 ASCO Gastrointestinal Cancer Symposium; January 18-20, 2024; San Francisco, California. Abstract LBA432

© 2023 HMP Global. All Rights Reserved.
Any views and opinions expressed are those of the author(s) and/or participants and do not necessarily reflect the views, policy, or position of Oncology Learning Network or HMP Global, their employees, and affiliates.

Recent News

News

Laparoscopic Hemihepatectomy vs Open Hemihepatectomy Among Patients With Primary or Metastatic Liver Tumors

05/17/2024

Stephanie Holland

Results from the ORANGE II PLUS trial demonstrated that a minimally invasive, laparoscopic approach to hemihepatectomy shortened time to functional recovery compared to open, major hemihepatectomy among patients with primary or metastatic...

Results from the ORANGE II PLUS...

05/17/2024

Oncology

News

FDA Grants Accelerated Approval to Tarlatamab for Patients With Extensive-Stage Small Cell Lung Cancer

05/17/2024

Stephanie Holland

Based on results from the DELLphi-301 trial, the FDA has granted accelerated approval to tarlatamab for patients with extensive-stage small cell lung cancer.

Based on results from the...

05/17/2024

Oncology

News

FDA Approves Lisocabtagene Maraleucel for Adult Patients With R/R Follicular Lymphoma

05/16/2024

Amber Denham

The US Food and Drug Administration granted accelerated approval to lisocabtagene maraleucel for adult patients with relapsed or refractory follicular lymphoma who have received 2 or more prior lines of systemic therapy.

The US Food and Drug...

05/16/2024

Oncology

News

No Improvement From Adjuvant Radiotherapy Post-Prostatectomy for Patients With Prostate Cancer At Risk of Recurrence

05/14/2024

Stephanie Holland

According to long-term results from the RADICALS-RT study, adjuvant radiotherapy does not meaningfully improve disease control and increases the risk of urinary and bowel morbidities among patients with prostate cancer at risk of recurrence...

According to long-term results...

05/14/2024

Oncology

News

Datopotamab Deruxtecan Shows Promising Activity, Safety Among Heavily Pretreated Patients With HR-Positive, HER2-Negative, or Triple-Negative Breast Cancer

05/14/2024

Stephanie Holland

According to results from the ongoing phase 1 TROPION-PanTumor01 trial, datopotamab deruxtecan demonstrated promising efficacy and safety among heavily pretreated patients with advanced or metastatic HR-positive, HER2-negative, or...

According to results from the...

05/14/2024

Oncology

News

Addition of Vismodegib to Radiation Therapy Shows Promise Among Patients With Basal Cell Carcinoma

05/10/2024

Stephanie Holland

Results from a prospective, phase 2 study found the addition of induction and concurrent vismodegib to radiation therapy may be considered a therapeutic option for patients with locally advanced, unresectable basal cell carcinoma.

Results from a prospective,...

05/10/2024

Oncology

News

Frontline Rituximab-Bendamustine Followed by Rituximab Maintenance Demonstrates Improved PFS vs R-CHOP Therapy Among Patients With Follicular Lymphoma

05/08/2024

Amber Denham

According to a retrospective study, rituximab-bendamustine followed by rituximab maintenance among patients with previously untreated advanced FL resulted in longer progression-free survival than rituximab, cyclophosphamide, doxorubicin,...

According to a retrospective...

05/08/2024

Oncology

News

Post-Allogeneic Hematopoietic Cell Transplant Gilteritinib Maintenance Demonstrates Benefit for Patients With AML With Detectable FLT3-ITD MRD

05/03/2024

Amber Denham

According to a recent trial, patients with acute myeloid leukemia with FLT3-ITD and measurable residual disease detectable in the peri-transplant period derived benefit from post-transplant gilteritinib, whereas those without detectable MRD...

According to a recent trial,...

05/03/2024

Oncology

News

FDA Approves Tisotumab Vedotin for Patients With Recurrent or Metastatic Cervical Cancer

05/01/2024

Stephanie Holland

Based on results from the phase 3 innovaTV 301 trial, the FDA has approved tisotumab vedotin for patients with recurrent or metastatic cervical cancer who experienced disease progression on or after systemic treatment.

Based on results from the phase...

05/01/2024

Oncology

News

Cabozantinib Shows Promising Activity Among Patients With Progressive, Unresectable Metastatic Phaeochromocytomas and Paragangliomas

04/25/2024

Stephanie Holland

According to results from the phase 2 Natalie trial, cabozantinib showed promising clinical activity among patients with progressive, unresectable metastatic phaeochromocytomas and paragangliomas.

According to results from the...

04/25/2024

Oncology